Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease (GA No 101120706)

Logo of the project "2D-BioPAD"

Funding Source

European Commission - Directorate‑General for Communications Networks, Content and Technology (CNECT/C/04)


HORIZON.2.4 - Digital, Industry and Space


1 October 2023 – 30 September 2027 (48 months)

Total budget

5,957,949.50 €



Q-PLAN role

Project Management Office, Dissemination & Communication Manager, and Exploitation Manager

Contact person(s)

Dr Apostolos Tsolakis (tsolakis@qplan-intl.gr), Elli Roma-Athanasiadou (roma@qplan-intl.gr), Alexandra Gkouma (gkouma@qplan-intl.gr)



2D-BioPAD aims to introduce a fast and cost-effective, non-invasive, reliable, digitally and graphene-enabled Point-of-Care (PoC) in-vitro diagnostics (IVD) system for supporting the early diagnosis and progression monitoring of Alzheimer’s Disease (AD) directly at primary healthcare settings.


To achieve this, and tackle the scientific challenge, the technological and market gap of PoC IVD for AD, 2D-BioPAD leverages the unique properties of 2D materials, such as graphene and its derivatives. Towards that direction, 2D-BioPAD goes beyond the state-of-the-art of its 2D Materials’ pioneer consortium to deliver a graphene-based PoC IVD system that will

  • introduce a versatile surface chemistry that combines nano and DNA technologies towards improved biocompatibility, stability, as well as high sensitivity and specificity for enhanced (bio-)sensing;
  • be able to reliably identify and quantify in real-time and simultaneously up to 5 AD biomarkers in blood samples effectively supporting healthcare professionals in early diagnosis;
  • offer an easy to use and understand digital interface with key metrics and insights regarding the measured results; and
  • employ Artificial Intelligence (AI) to improve the overall system implementation.


The 2D-BioPAD system and its impact will be demonstrated in 3 clinical centres in Europe (Finland, Greece, and Germany) under two clinical pilot studies. In every step, and from the very beginning, 2D-BioPAD will go beyond current norms and involve a wide range of stakeholders, starting from the clinic itself, and led by industrial partners, to identify the essential safety and ethical-by-design principles and guidelines that can accelerate uptake at primary healthcare settings and maximise acceptance and impact to both physical and digital supply chains.

Being one of the core governing members of the Graphene Flagship Initiative, 2D-BioPAD is part of a large network of academic and industrial stakeholders, contributing to the advancement of Europe’s strategic autonomy in technologies that rely on graphene and other 2D materials.

Q-PLAN responsibilities

  • Project Management Office
  • Dissemination and communication
  • Exploitation and Innovation Management
  • Business Modelling and Planning
  • Data Management